Medical Lymphoma

The Department of Lymphoma Medicine at Tianjin Medical University Cancer Hospital is a professional discipline in a tertiary-level hospital that integrates medical treatment, teaching, scientific research, and clinical translational medicine. It has rich clinical experience in the diagnosis and treatment of lymphatic system tumors. In 2017, the number of outpatient visits exceeded 18,187. The annual outpatient visits and the number of admissions and admissions rank among the top lymphoma specialties in the country.

The predecessor of the Department of Lymphoma Medicine was the Department of Chemotherapy established in 1978. In the 1970s, Professor Jin Xianzhai, the founder of oncology in my country, established a professional chemotherapy group. It was on this basis that the Department of Chemotherapy gradually developed and expanded.

In 1998, the Department of Internal Oncology, now the Department of Lymphoma, was officially established.

Currently, the department has a total of 93 beds, including 58 in the main ward, 16 in senior wards, and 19 in comprehensive wards;

There are 21 physicians in total, including 2 chief physicians, 4 deputy chief physicians, 11 attending physicians, and 4 residents. Among them, 16 have doctorate degrees, 8 have overseas study experience, and 1 is a specially appointed lecture professor in Tianjin.

Clinical diagnosis and treatment and new technologies:

The diagnosis and treatment model of lymphoma medicine is in line with international standards. It comprehensively uses cell morphology/cytochemistry, karyotype analysis, molecular genetics, molecular biology and other technologies combined with clinical diagnosis, classification, prognosis assessment and disease monitoring to tailor individualized treatment plans for patients. Chemotherapy, immunotherapy, molecular targeted therapy, radiotherapy and other means are combined to treat lymphoma.

Clinical, pathology, imaging, radiotherapy, biological therapy, and multidisciplinary MDT consultation in the hospital enable lymphoma patients to receive more accurate diagnosis and more standardized treatment, significantly extending the patient's survival time and improving the patient's quality of life.

The new technologies currently developed by the department include: CAR-T cell therapy technology, lymphoma circulating tumor DNA (ctDNA) detection technology, etc.

Lymphoma Medical Patient Education Meeting

Scientific research and external exchanges:

Since 2016, it has won 4 National Natural Science Foundation of China bids and has a total of 7 National Natural Science Foundation projects under research;

Published 13 SCI papers, including 2 SCI papers published by the corresponding author unit with IF>10 points, 1 with IF>5 points, and 2 SCI papers with 5>IF>3 points.

The number of new international and domestic clinical research projects launched in 2017 ranks first among all departments in our hospital.

The department edits and publishes academic and popular science books: it participates in organizing the compilation of "Lymphoma Diagnosis and Treatment", "Cancer Prevention, Treatment and Rehabilitation", etc.

In 2016, it won the third prize of Tianjin Science and Technology Progress Award.

In recent years, our department has carried out long-term exchanges and cooperation with many well-known foreign cancer centers, and has sent many doctors abroad for clinical studies or scientific research training, and has achieved fruitful results.

Academic conference:

Relying on a professional multidisciplinary diagnosis and treatment team, the biennial Tianjin International Lymphoma Summit Forum was held in 2016, forming Tianzhu’s international lymphoma conference brand and increasing the department’s influence and visibility at home and abroad.

The 2017 Tianjin How I Treat and Lymphoma Translational Medicine International Symposium provides domestic lymphoma doctors with basic and clinical research cutting-edge that is both professional and practical.

In 2016, he took the lead in establishing the Lymphoma Professional Committee of the Tianjin Anti-Cancer Association and held more than 40 offline meetings with surrounding areas, including the Tianjin International Lymphoma Summit Forum, the Tianjin-Hebei Lymphoma MDT, and the Young Physician Training Course, etc., to drive the surrounding areas to jointly improve the level of lymphoma diagnosis and treatment.

In 2017, the North China Lymphoma Collaboration Platform was established, linking 9 centers including Tianjin, Hebei, Shanxi, Inner Mongolia, and Shandong to initiate online and offline MDT case discussions and mutual cooperation in multi-center clinical trials and basic scientific research.

The influence of Tianzhuang Lymphoma Department has gradually increased, and it has gradually developed into one of the most influential lymphoma diagnosis and treatment centers in northern China.